Growth Strategy: AstraZeneca Launches APAC Headquarters In Shanghai
This article was originally published in PharmAsia News
The second largest pharma company in China has opened a new Asia-Pacific headquarters in Shanghai’s Zhangjiang Hi-tech Park as it looks to jumpstart growth that has recently slowed.
You may also be interested in...
AstraZeneca Invests $100 Million To Expand Shanghai Site In Move To Capture Larger Share Of Emerging Markets
SHANGHAI - AstraZeneca is investing $100 million to expand its current site in the Shanghai Zhangjiang Hi-Tech Park to strengthen its China headquarters and beef up marketing, R&D and academic training
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.